<DOC>
	<DOC>NCT00016588</DOC>
	<brief_summary>The purpose of this study is to look at the effectiveness of tenofovir disoproxil fumarate (TDF) in HIV-infected patients who have never taken anti-HIV drugs.</brief_summary>
	<brief_title>Tenofovir Disoproxil Fumarate (TDF) in HIV-1 Patients Who Have Never Taken Anti-HIV Drugs</brief_title>
	<detailed_description>Patients receive TDF.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Inclusion Criteria Patients may be eligible for this study if they: Are HIVpositive. Have a plasma viral load (level of HIV in the blood) of 10,000 copies/ml or more. Have a CD4 count of 50 cells/mm3 or more. Have a negative pregnancy test. Agree to use 2 forms of barrier birth control while on the study and for 30 days afterwards. Are 18 to 65 years old. Exclusion Criteria Patients will not be eligible for this study if they: Have had treatment with any of the following types of antiHIV drugs: nucleoside reverse transcriptase inhibitors, nucleotide reverse transcriptase inhibitors (e.g., adefovir dipivoxil or TDF), protease inhibitors, or nonnucleoside reverse transcriptase inhibitors. Have received a vaccination within 30 days before study entry. Have had a new AIDSdefining illness diagnosed within 30 days before study entry. Are taking any of the following: drugs that may cause kidney problems, including aminoglycoside antibiotics, cidofovir, cisplatin, foscarnet, intravenous (IV) amphotericin B, IV vancomycin, oral and IV ganciclovir, and valganciclovir; probenecid; chemotherapy; steroid drugs; interleukin2; or investigational drugs. Are pregnant or breastfeeding. Have difficulty taking, absorbing, or tolerating drugs by mouth, as may be shown by longterm nausea or vomiting. Abuse alcohol or drugs. Have cancer other than Kaposi's sarcoma or basal cell carcinoma. Have other infections that need injectable antibiotics within 15 days before study entry. Have had kidney or bone disease. Have any medical conditions or past treatments that the study investigator believes would make the patient unsuitable for the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2002</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Adenine</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
	<keyword>Organophosphorus Compounds</keyword>
</DOC>